drug · small molecule
CALQUENCE
Marketedupdated 6mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 20 investigational indications.
indications
investigational
DLBCL
targets
Tyrosine-protein kinase BTK
all catalysts(13)
approval · 12
Oct 31, 2017
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Nov 21, 2019
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Nov 21, 2019
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Mar 24, 2022
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Aug 3, 2022
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Aug 3, 2022
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Jun 5, 2024
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Jun 5, 2024
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Jan 16, 2025
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Jan 16, 2025
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Feb 19, 2026
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval
CALQUENCE
→
Feb 19, 2026
approval
$AZN178.76-1.93%
CALQUENCE (ACALABRUTINIB) — FDA approval
CALQUENCE
→
Trials studying CALQUENCE
- phase2Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
- phase2Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
- phase3A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
- phase1Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
- phase3A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- phase2A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
- phase2A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
- phase2Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 21, 2026
1 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (17)
- Jul 1, 2036formulationUS 10167291
- Jul 1, 2036compositionUS 11059829
- Jul 1, 2036compositionUS 9796721
- Aug 11, 2035method-of-use (U-4431)US 11166951
- Aug 11, 2035method-of-use (U-4427)US 11166951
- Jan 21, 2035method-of-use (U-4109)US 10272083
- Jan 21, 2035method-of-use (U-2687)US 10272083
- Jan 21, 2035method-of-use (U-3710)US 11771696
- Jan 21, 2035method-of-use (U-3710)US 11771696
- Jul 11, 2032method-of-use (U-2668)US 10239883
- Jul 11, 2032method-of-use (U-2666)US 10239883
- Jul 11, 2032compositionUS 9290504
- Jul 11, 2032compositionUS 9290504
- Jul 11, 2032method-of-use (U-2145)US 9758524
- Jul 11, 2032method-of-use (U-2145)US 9758524
- Nov 24, 2026compositionUS 74595544d
- Nov 24, 2026compositionUS 74595544d
FDA exclusivities (3)
- Jan 16, 2028I-960Indication (3y)1.2y
- Jan 16, 2028I-960Indication (3y)1.2y
- Nov 21, 2026ODE-274Orphan Drug (7y)1d
News(5)
- First wave of #ASH26 abstracts is here, with data from J&J, Servier and AstraZenecaThe American Society of Hematology's annual meeting is just a little over a month away. This year's edition will be in New Orleans, LA, and Endpoints News will be covering the meeting in person. Fo…endpoints · 14d ago
- Nurix drops one BTK degrader as momentum builds behind Roche-partnered optionNurix’s BTK degrader zelebrudomide may have survived a clinical hold in recent years, but that hasn’t stopped the California biotech from dropping the cancer drug.fiercebiotech · 1mo ago
- Pharma’s $500B patent problem will come in waves — not as a cliffMerck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.biopharma_dive · 1mo ago
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trialThe better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.biopharma_dive · 1mo ago
- Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCLRetrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.onclive · 6mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that